While the cell lines considered here were entirely androgen pathway independent, other prostate cancers develop hypersensitivity to androgen receptor pathway signaling; this latter type of hormone therapy resistant cancer was not considered in this study. The gene discussed is AR; the disease is prostate carcinoma.